FIG. 5.

Antigenicity of e-β2m. Standard 4-h ⁵¹Cr release assays were performed using a Nef138-10-specific CTL clone derived from an HIV-1 infected individual. (A) As target cells, HLA-A24-matched B-LCLs were pulsed with the culture supernatant of Nef138-β2m/SeV (solid squares)- or Env584-β2m/SeV (open squares)-infected CV-1 (left) or MT-2 (right) cells. CV-1 or MT2 cells were infected with SeVs at an MOI of 3, and the culture supernatant was harvested 24 h postinfection and filtered with a 0.22-μm-pore-size membrane. The culture supernatants were used at a 10-fold dilution, and Nef138-β2m and Env584-β2m from CV-1 or MT-2 cells were used at about 30 or 2 nM, respectively. (B) B-LCLs infected with either Nef138-β2m/SeV (solid diamonds), Env584-β2m/SeV (open diamonds), or wild-type SeV (crosses) were also used as target cells. B-LCLs were infected with SeVs at an MOI of 10 and used as target cells 24 h postinfection. As a control, B-LCLs were pulsed with the Nef138-10 peptide at 100 nM (solid triangles).